Aveo Pharmaceuticals (AVEO) 2.04 $AVEO New finance chief

New Post Public Reply Private Reply Replies (0) Message Board

Apr 22, 2015 at 7:06 PM

Aveo Pharmaceuticals (AVEO) 2.04 $AVEO

New finance chief at Aveo Oncology
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 7:43AM CDT

AVEO: 2.04 (+0.12)

AVEO Names Keith S. Ehrlich as Chief Financial Officer
Business Wire - Wed Apr 22, 6:00AM CDT
AVEO Oncology (NASDAQ:AVEO) today announced the appointment of Keith S. Ehrlich to the position of chief financial officer. In this role, Mr. Ehrlich will be responsible for the company's financial and administrative strategy and management, and will serve on the executive leadership team which governs corporate strategy. He will report to Michael Bailey, AVEO's president and chief executive officer.
AVEO: 2.04 (+0.12)

The Medicines Co.'s New Minocin Formulation Approved - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 5:21PM CDT
The Medicines Company (MDCO) received approval from the FDA for a new formulation of Minocin.
MDCO: 27.84 (+0.25), HZNP: 30.96 (+0.10), AVEO: 2.04 (+0.12), OSIR: 16.35 (-0.10)

Bristol-Myers Announces Positive Data from Opdivo Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 5:05PM CDT
Bristol-Myers (BMY) announced encouraging results from a phase II study Opdivo in combination with Yervoy.
BIIB: 423.57 (+1.46), MRK: 57.69 (+0.03), AVEO: 2.04 (+0.12), BMY: 66.60 (-0.21)

Actavis' Botox Upper Limb Spasticity Label Expanded by FDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 3:08PM CDT
Actavis' (ACT) Botox has been granted further FDA approval; adds upper limb spasticity to its label.
CRMD: 8.86 (-0.28), BIIB: 423.57 (+1.46), ACT: 295.22 (+0.69), AVEO: 2.04 (+0.12)

AVEO Pharmaceuticals (AVEO) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 8:43AM CDT
AVEO Pharmaceuticals (AVEO) Shares March Higher, Can It Continue?
AVEO: 2.04 (+0.12)

Merck's Keytruda Tops Melanoma, Lung Cancer Studies - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 20, 5:26PM CDT
Merck (MRK) presented encouraging results at the annual meeting of the American Association for Cancer Research from studies evaluating its anti-PD-1 therapy, Keytruda.
MRK: 57.69 (+0.03), HZNP: 30.96 (+0.10), AVEO: 2.04 (+0.12), BMY: 66.60 (-0.21)

Athersys Slumps as MultiStem Fails in Mid-Stage Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 20, 5:14PM CDT
Athersys (ATHX) announced disappointing interim results from a phase II study on MultiStem cell therapy.
BIIB: 423.57 (+1.46), AZN: 73.35 (+0.65), AVEO: 2.04 (+0.12), ATHX: 1.34 (+0.01)

Bristol-Myers' Study on Opdivo Halted on Early Success - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 20, 4:58PM CDT
Bristol-Myers' Study on Opdivo was Halted early as it meets key endpoints.
BIIB: 423.57 (+1.46), MRK: 57.69 (+0.03), AVEO: 2.04 (+0.12), BMY: 66.60 (-0.21)

Oncolytics' Reolysin Gets One More Orphan Drug Status - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 20, 2:20PM CDT
Oncolytics' (ONCY) lead candidate Reolysin has been granted orphan drug status by the FDA for the treatment of malignant gliomas.
ONCY: 0.80 (unch), ANIP: 69.79 (+1.24), AVEO: 2.04 (+0.12), AMGN: 169.10 (+0.64)

TrovaGene's (TROV) PCM Data Impresses, Shares Rally - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 20, 2:08PM CDT
Shares of TrovaGene Inc. (TROV) surged 20.14% to close at $8.53 on Apr 17, after the company reported favorable clinical data for its Precision Cancer Monitoring (PCM) technology.
TROV: 8.58 (-0.27), ANIP: 69.79 (+1.24), AVEO: 2.04 (+0.12), AMGN: 169.10 (+0.64)

Zacks Rank #1 Additions for Monday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Apr 20, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday
ACHC: 71.98 (-0.47), ANET: 66.27 (+0.40), ABG: 86.97 (-0.16), AVEO: 2.04 (+0.12), ADUS: 27.60 (-0.33)

AVEO Oncology Announces Presentation of AV-380 Preclinical Data in Cancer Associated Cachexia at 2015 Annual Meeting of the American Association of Cancer Research
Business Wire - Mon Apr 20, 6:00AM CDT
AVEO Oncology (NASDAQ:AVEO) today announced the presentation of results from a preclinical study of AV-380, the Company's potent, humanized inhibitory antibody targeting growth differentiation factor 15 (GDF15), in a cachectic human tumor xenograft model with significantly increased plasma GDF15 levels. The data were presented in a poster titled "Effective treatment of cancer associated cachexia by AV-380, a GDF15 inhibitory antibody" at the 2015 Annual Meeting of the American Association of Cancer Research in Philadelphia from April 18-22.
AVEO: 2.04 (+0.12)

Receptos Gains on Positive Phase II Data on Ozanimod - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 17, 4:28PM CDT
Receptos (RCPT) announced positive results from the maintenance period of the TOUCHSTONE study on ozanimod for ulcerative colitis.
ANIP: 69.79 (+1.24), AVEO: 2.04 (+0.12), RCPT: 166.76 (-3.37), AFFX: 12.57 (-0.13)

AVEO Pharmaceuticals (AVEO) Jumps: Stock Moves Up 16.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 17, 7:51AM CDT
AVEO Pharmaceuticals, Inc. (AVEO) was a big mover last session, as its shares rose over 16% on the day.
AVEO: 2.04 (+0.12), AFFX: 12.57 (-0.13)

AstraZeneca's Onglyza Label Needs Revision per FDA Panel - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 16, 5:04PM CDT
AstraZeneca's (AZN) Onglyza and Kombiglyze XR labels have been recommended to include new safety information as per an FDA panel.
MRK: 57.69 (+0.03), AZN: 73.35 (+0.65), AVEO: 2.04 (+0.12), LLY: 72.30 (+0.09)

The Medicines Co.'s Kengreal Backed for FDA Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 16, 4:57PM CDT
The Medicines Company's (MDCO) Kengreal is a step closer to U.S. approval with the FDA panel giving a favorable opinion for the treatment of percutaneous coronary intervention.
MDCO: 27.84 (+0.25), ANIP: 69.79 (+1.24), HZNP: 30.96 (+0.10), AVEO: 2.04 (+0.12)

Glaxo Downgraded to Strong Sell, Delete from Your Portfolio - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 16, 4:05PM CDT
On Apr 15, Zacks Investment Research downgraded GlaxoSmithKline plc (GSK) to a Zacks Rank #5 (Strong Sell); delete from your portfolio.
ANIP: 69.79 (+1.24), AVEO: 2.04 (+0.12), GSK: 46.57 (-0.67), AFFX: 12.57 (-0.13)

GW Pharmaceuticals Up to Strong Buy on Strong Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 16, 3:27PM CDT
On Apr 16, Zacks Investment Research upgraded GW Pharmaceuticals plc (GWPH) to a Zacks Rank #1 (Strong Buy); is it in your portfolio?
GWPH: 113.04 (-0.05), ANIP: 69.79 (+1.24), AVEO: 2.04 (+0.12), AFFX: 12.57 (-0.13)

Two Sub $2 Biotech Stocks On The Move
Bret Jensen - at Seeking Alpha - Thu Apr 16, 2:29PM CDT

ZGNX: 1.63 (-0.02), AVEO: 2.04 (+0.12)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Miranda Lambert Lights Up Red Kettle Campaign

By Logan Wright Updated Oct 25, 2026 Category News Views 222

A Star-Studded Start to the Season of Giving Miranda Lambert is set to dazzle audiences yet again, and if there's one thing this country music titan knows, it's how to crank up the heartstrings while fanning the flames of generosity. She'll take to the stage at AT&T Stadium this Thanksgiving during the Dallas Cowboys game, bringing a powerful performance to light up the...

TORRAS Cases Balance Protection with Slim Design for 2026

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

DigitalXForce Shakes Up GRC: AI-Infused X-ROC Launch

Turning Risk Management on Its Head Well, here's a company not just tinkering around the edges but flipping the script on Governance, Risk, and Compliance (GRC) with their latest rollout: DigitalXForce and its X-ROC. Yeah, it's yet another acronym to juggle, but don't roll your eyes just yet. This AI-driven beast isn't about occasional boardroom reports. No sir, it's a...

CapCut's Role in AI-Assisted Small Biz Marketing

In today's fast-paced digital world, small businesses lament the constant hustle to stay relevant online. This juggling act with limited resources often makes effective marketing feel like a high-wire circus performance. Enter AI tools, promising to lighten the load, and CapCut stands out as a game-changer. AI Tools Revolutionizing Small Business Marketing Amid growing...

Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Vantrue's Black Friday Dash Cam Deals: Save up to 44%

Kicking Off Early Black Friday with Dash Cam Bargains In a bid to stay ahead of the holiday shopping rush, Vantrue announced its early Black Friday campaign with a range of discounts designed to capture the interest of road warriors and casual drivers alike. From November 1 to November 21, 2026, Vantrue is inviting bargain hunters to explore their offerings—culminating...

Borr Drilling's Rig Sinks, Uncertainty Looms Offshore

Unexpected Turn of Events at Sea Now here's a gut-punch nobody saw coming. Borr Drilling Limited (NYSE and OSE: BORR) got hit hard when their Prospector 5 drilling rig went under the waves offshore Gabon. This ain't no desk job dilemma; we're talking about a real-life offshore catastrophe. It all went down on October 24, 2026, when the rig experienced a punch through...

Fluence Energy Hits Legal Snag: Investors Called to Act

Fluence Energy Faces a Securities Fraud Challenge It's like watching a slow-motion train wreck. Fluence Energy, Inc. (NASDAQ: FLNC) now finds itself in the crosshairs of a securities fraud class action lawsuit. Apparently, someone was playing fast and loose with the truth concerning their financial guidance. The period in question stretches from November 24, 2025, to...

Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...